Scarica l'app Stockscreener
1.65
4.43%
0.07
Precedente Chiudi:
$1.58
Aprire:
$1.58
Volume 24 ore:
55,316
Relative Volume:
0.46
Capitalizzazione di mercato:
$6.93M
Reddito:
$125.00K
Utile/perdita netta:
$-14.64M
Rapporto P/E:
-0.3193
EPS:
-5.1674
Flusso di cassa netto:
$-15.06M
1 W Prestazione:
+2.48%
1M Prestazione:
-16.24%
6M Prestazione:
-49.23%
1 anno Prestazione:
-75.00%
Intervallo 1D:
$1.57
$1.67
Intervallo di 1 settimana:
$1.5641
$1.68
Portata 52W:
$1.47
$6.96
Imunon Inc Stock (IMNN) Company Profile
Nome
Imunon Inc
Settore
Industria
Telefono
(609) 896-9100
Indirizzo
997 LENOX DRIVE, LAWRENCEVILLE
Compare IMNN vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMNN
Imunon Inc
|
1.65 | 6.77M | 125.00K | -14.64M | -15.06M | -5.1674 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Imunon Inc Borsa (IMNN) Ultime notizie
Armistice Capital (IMNN) discloses 9.99% Imunon stake via Master Fund - Stock Titan
IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025 - kalkine.ca
Imunon Inc (NASDAQ: IMNN) Share Price, IMNN Stock News, IMNN Share Price & Updates - Kalkine
Earnings call transcript: Imunon beats Q2 2026 EPS forecast as shares stay weak - Investing.com UK
Imunon (IMNN) Q2 2026 Earnings Call Transcript - The Globe and Mail
Imunon Q2 2026 Loss Shrinks 42.6%: -$0.54/Share vs -$0.94 Expected - AlphaStreet
Imunon Q2 2026 Earnings Call Transcript - MarketBeat
Imunon Adopts New Equity-Based Executive Compensation Program - TipRanks
Imunon, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Imunon, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Form 8K Imunon Inc For: 11 August By Investing.com - Investing.com Nigeria
Q2 2026 Imunon Inc Earnings Call Transcript - GuruFocus
Imunon Inc (IMNN) Advances Phase 3 Trial Amidst Challenging Valu - GuruFocus
Imunon, Inc. 2Q 2026: Net loss $(2.83M), EPS $(0.54) — 10-Q Summary - TradingView
IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Imunon Q2 net loss widens slightly as R&D costs rise - TradingView
IMUNON reports $2.8 million Q2 loss as OVATION 3 enrollment advances - quiverquant.com
Imunon reports Q2 2026 net loss $2.8M; cash $6.9M, advances Phase 3 OVATION 3 - TradingView
BRIEF-Imunon Q2 EPS USD -0.54 - TradingView
Imunon Inc expected to post a loss of 93 cents a shareEarnings Preview - TradingView
Imunon Inc. (CBO0.SG) balance sheet - Yahoo Finance UK
Imunon (IMNN.US) will release its earnings report on August 11. - Moomoo
Imunon (IMNN) General Counsel Susan Eylward Sells 2,541 Shares - GuruFocus
Imunon, Inc. (IMNN) director granted 6,934 shares in lieu of fees - Stock Titan
Imunon (IMNN) director granted 6,934 shares of stock for board fees - Stock Titan
Imunon (IMNN) grants director 6,934 shares instead of cash board fees - Stock Titan
Imunon (NASDAQ: IMNN) awards director 6,180 shares for board fees - Stock Titan
Imunon, Inc. (IMNN) general counsel grants and sells 2,541 shares - Stock Titan
Imunon, Inc. (IMNN) grants chair 6,358 shares instead of cash salary - Stock Titan
Imunon, Inc. (IMNN) CMO granted stock in lieu of cash pay - Stock Titan
Imunon, Inc. (IMNN) CEO awarded 5,010-share stock grant as compensation - Stock Titan
IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026 - The Manila Times
IMUNON Plans Phase 3 Ovarian Cancer Update on Aug. 11 - Stock Titan
Imunon (IMNN.US) will release its earnings report on August 4. - Moomoo
IMUNON reports faster-than-expected enrollment in ovarian cancer trial By Investing.com - Investing.com Nigeria
IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer - GlobeNewswire
Imunon Reports Strong Enrollment Momentum In Phase 3 Ovation 3 Trial Of Imnn-001 In Advanced Ovarian Cancer - TradingView
IMNN|Imunon Inc|Price:1.514|Chg%:+0.004 - TradingKey
Imunon Inc (IMNN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Imunon Inc (IMNN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Imunon Inc (IMNN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Imunon Inc (IMNN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Imunon Inc (IMNN) Cash Flow - TradingKey
IMNN|Imunon Inc|Price:1.510|Chg%:-0.150 - TradingKey
Imunon Inc. (IMNN) Q1 2026 Earnings: Narrower-Than-Expected Loss as Clinical Progress ContinuesEarnings Cycle Report - dars.gov.et
Imunon, Inc. Revenue Breakdown – NASDAQ:IMNN - TradingView
Imunon Inc (IMNN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Imunon, Inc. (IMNN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Imunon, Inc. (IMNN) stock price, news, quote and history - Yahoo Finance UK
Analysts Offer Insights on Healthcare Companies: Agios Pharma (AGIO) and Imunon (IMNN) - The Globe and Mail
Price to earnings forward of Imunon, Inc. – NASDAQ:IMNN - TradingView
Imunon Inc Azioni (IMNN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):